Tesamorelin (brand name: Egrifta) is the only FDA-approved growth hormone releasing hormone (GHRH) analog specifically indicated for reducing visceral adipose tissue. Unlike most peptides in the research space, tesamorelin has robust Phase III clinical trial data behind it.
Why Visceral Fat Matters
Visceral fat — the fat surrounding your internal organs — is the most metabolically dangerous type of body fat. It's strongly correlated with cardiovascular disease, type 2 diabetes, and all-cause mortality. You can't crunch it away. It requires metabolic intervention.
How Tesamorelin Works
Tesamorelin is a synthetic analog of GHRH (growth hormone releasing hormone) with a trans-3-hexenoic acid modification that extends its activity. It stimulates the pituitary to release growth hormone in a pulsatile, physiological pattern.
- Pituitary stimulation: Triggers natural GH release patterns
- Visceral fat targeting: GH preferentially mobilizes visceral adipose tissue
- IGF-1 normalization: Restores IGF-1 to healthy physiological ranges
- Metabolic improvement: Reduces triglycerides and improves lipid profiles
Clinical Evidence
| Study | Duration | Visceral Fat Reduction | Key Finding |
|---|---|---|---|
| Phase III (Falutz 2007) | 26 weeks | -15.2% | Significant VAT reduction vs placebo |
| Extension Study | 52 weeks | -18.4% | Continued improvement over 1 year |
| LIPO-010 | 26 weeks | -8.3% | Reduced trunk fat with preserved limb fat |
Key Advantage: Unlike exogenous GH, tesamorelin maintains the body's natural feedback loops. When you stop taking it, your HPA axis isn't suppressed — though visceral fat may gradually return without lifestyle changes.
